2021
Interplay between RNA Methylation Eraser FTO and Writer METTL3 in Renal Clear Cell Carcinoma Patient Survival
Zhao J, Lu L. Interplay between RNA Methylation Eraser FTO and Writer METTL3 in Renal Clear Cell Carcinoma Patient Survival. Recent Patents On Anti-Cancer Drug Discovery 2021, 16: 363-376. PMID: 33563180, DOI: 10.2174/1574892816666210204125155.Peer-Reviewed Original ResearchConceptsMETTL3 mRNASurvival analysisFTO mRNAKaplan-Meier survival curvesAdjusted hazard ratioMultivariate Cox regressionRenal clear cell carcinomaClear cell carcinomaInflammation-related genesPotential prognostic markerM6A methyltransferase METTL3Upregulation of FTOHazard ratioCox regressionPatient survivalPrognostic valueCell carcinomaPrognostic markerSuperior survivalImmune responseMETTL3 expressionDifferential expressionClinical relevanceLower DNA methylationSurvival curves
2020
Gene Alterations of N6‐Methyladenosine (m6A) Regulators in Colorectal Cancer: A TCGA Database Study
Zhang Q, Cai Y, Kurbatov V, Khan SA, Lu L, Zhang Y, Johnson CH. Gene Alterations of N6‐Methyladenosine (m6A) Regulators in Colorectal Cancer: A TCGA Database Study. BioMed Research International 2020, 2020: 8826456. PMID: 33415160, PMCID: PMC7769650, DOI: 10.1155/2020/8826456.Peer-Reviewed Original ResearchMeSH KeywordsAdenosineAgedAlpha-Ketoglutarate-Dependent Dioxygenase FTOColorectal NeoplasmsDatabases, GeneticDisease-Free SurvivalDNA Copy Number VariationsFemaleGene Expression Regulation, NeoplasticGenes, NeoplasmHumansMaleMultivariate AnalysisMutationNerve Tissue ProteinsPrognosisProportional Hazards ModelsRNA Splicing FactorsRNA, MessengerConceptsDisease-free survivalImmune cell infiltrationM6A regulatorsCRC patientsCRC casesCell infiltrationMRNA expressionWorse overall survivalN6-methyladenosine regulatorsMicrosatellite instability statusMessenger RNA expressionCancer Genome AtlasOverall survivalColorectal cancerCRC tissuesDatabase studyImmune functionInstability statusColon tissuesRole of m6AGene alterationsRNA expressionCRCGenome AtlasGenetic mutations
2015
Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control Consortium
Waterhouse M, Risch HA, Bosetti C, Anderson KE, Petersen GM, Bamlet WR, Cotterchio M, Cleary SP, Ibiebele TI, La Vecchia C, Skinner HG, Strayer L, Bracci PM, Maisonneuve P, Bueno-de-Mesquita HB, Zaton Ski W, Lu L, Yu H, Janik-Koncewicz K, Polesel J, Serraino D, Neale RE. Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control Consortium. Annals Of Oncology 2015, 26: 1776-1783. PMID: 25977560, PMCID: PMC4511221, DOI: 10.1093/annonc/mdv236.Peer-Reviewed Original ResearchConceptsVitamin D intakeDietary vitamin D intakePancreatic Cancer Case-Control ConsortiumPancreatic cancerD intakeVitamin DOdds ratioInternational Pancreatic Cancer Case-Control ConsortiumStudy-specific odds ratiosTotal vitamin D intakeMultivariable logistic regressionCase-control studyPancreatic cancer riskRandom-effects modelEstimates of associationDietary intakeCancer riskLogistic regressionCancerIntakeAdditional studiesPotential roleAssociationRiskNegative association
2012
Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer
Lu L, Zhu G, Zhang C, Deng Q, Katsaros D, Mayne ST, Risch HA, Mu L, Canuto EM, Gregori G, Benedetto C, Yu H. Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer. Breast Cancer Research And Treatment 2012, 136: 875-883. PMID: 23124417, DOI: 10.1007/s10549-012-2314-z.Peer-Reviewed Original ResearchConceptsPrimary breast cancerBreast cancerHOTAIR expressionPathologic featuresCox proportional hazards regression modelProportional hazards regression modelsLow HOTAIR expressionUnfavorable disease characteristicsHazards regression modelsIndependent prognostic markerHigh HOTAIR expressionBreast cancer progressionQuantitative RT-PCRPatient survivalDisease characteristicsMethylation-specific PCRPrognostic markerLower riskSignificant associationRNA HOTAIRCancerCancer progressionBiologic relevanceRT-PCRDNA methylationHigh lead exposure is associated with telomere length shortening in Chinese battery manufacturing plant workers
Wu Y, Liu Y, Ni N, Bao B, Zhang C, Lu L. High lead exposure is associated with telomere length shortening in Chinese battery manufacturing plant workers. Occupational And Environmental Medicine 2012, 69: 557. PMID: 22539657, DOI: 10.1136/oemed-2011-100478.Peer-Reviewed Original ResearchConceptsLead exposurePlant workersLong-term lead exposureBody mass indexHigh lead exposureBattery plant workersTelomere length shorteningWeak positive associationInpatient workersMass indexAge-associated diseasesInverse associationBurden assessmentStrong inverse correlationMultivariate analysisOccupational pollutantsLength shorteningLead levelsInverse correlationTelomere lengthLead toxicityBLLPositive associationPublic healthQuantitative PCRFavorable outcome associated with an IGF-1 ligand signature in breast cancer
Mu L, Tuck D, Katsaros D, Lu L, Schulz V, Perincheri S, Menato G, Scarampi L, Harris L, Yu H. Favorable outcome associated with an IGF-1 ligand signature in breast cancer. Breast Cancer Research And Treatment 2012, 133: 321-331. PMID: 22297468, DOI: 10.1007/s10549-012-1952-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularCohort StudiesDisease-Free SurvivalFemaleGene ExpressionGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansInsulin-Like Growth Factor Binding ProteinsInsulin-Like Growth Factor IKaplan-Meier EstimateLigandsMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalOligonucleotide Array Sequence AnalysisPrognosisReceptor, IGF Type 1Young AdultConceptsIGF-1 ligandBreast cancerFavorable outcomeInsulin-like growth factor (IGF) axisActivation signaturePrimary breast cancerGrowth factor axisPredictors of responseHuman breast cancerPathway analysisUpregulation of pathwaysBetter prognosisIGF axisPrognostic valueReceptor levelsLevels of mRNAFactor axisIGF ligandsIngenuity softwarePathway activation scoresCancerLigand levelsActivation scoresHigh groupProliferation pathways
2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2011, 31: 4559-4566. PMID: 22139083, PMCID: PMC3342446, DOI: 10.1038/onc.2011.539.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinCarboplatinCell Line, TumorCell SurvivalDrug Resistance, NeoplasmFemaleGenotypeHumansKaplan-Meier EstimateMiddle AgedMultivariate AnalysisMutationNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelPolymorphism, Single NucleotidePrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRNA InterferenceTreatment OutcomeConceptsEpithelial ovarian cancerEOC patientsKRAS-variantOvarian cancerPoor outcomeCancer riskTumor biologyPlatinum resistanceComplete clinical dataBiomarkers of outcomeDirect targetingEOC cell growthKnown BRCA mutationsFuture treatment approachesSubset of tumorsPlatinum chemotherapy resistanceCell linesNeoadjuvant chemotherapyBRCA mutationsClinical dataTreatment approachesChemotherapy resistanceKRAS oncogeneMultivariate analysisPatients